R-Acalabrutinib(CAS: 1952316-43-6)

R-Acalabrutinib is a crystalline compound with a molecular weight of approximately 467.37 g/mol. It has a low solubility in water but good solubility in organic solvents like DMSO. Chemically, it is highly reactive towards nucleophilic substitution reactions. It is typically used in pharmaceutical applications where its properties are advantageous.

R-Acalabrutinib is synthesized via a multi-step process involving the protection of a key functional group, followed by a nucleophilic substitution reaction. The synthesis often utilizes palladium catalysts and achieves a high yield. The reaction conditions are carefully optimized to ensure selectivity towards the desired product.

R-Acalabrutinib is primarily used in the pharmaceutical industry for the treatment of hematologic malignancies. It is also relevant in the development of new drug candidates for autoimmune diseases. Its use in other industries is limited due to its specific application in medicinal chemistry.

When handling R-Acalabrutinib, appropriate personal protective equipment (PPE) should be worn, including gloves and safety goggles. It should be handled in a well-ventilated area or under a fume hood. In case of a spill, it should be carefully cleaned up using appropriate absorbents, and the area should be thoroughly rinsed. Always refer to the Safety Data Sheet (SDS) for detailed handling instructions.